Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSDSFX)

• Drug Name: JNJ-75348780 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMSDSFX

Molecule-Related Drug Atlas

Drug(s) Targeting B-cell receptor CD22 (CD22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moxetumomab pasudotox	DMN63DZ	Hairy cell leukaemia	2A82.2	Approved	[2]
Inotuzumab ozogamicin	DMAC130	Acute lymphoblastic leukaemia	2A85	Approved	[3]
OspA lipoprotein	DMF5ZB3	Lyme disease	1C1G	Approved	[4]
Epratuzumab	DMI1ZXV	Acute lymphoblastic leukaemia	2A85	Phase 3	[5]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[6]
BL-22	DM8R71T	Acute lymphoblastic leukaemia	2A85	Phase 2	[7]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[8]
AUTO3	DMC5NSO	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[9]
CART-19/22	DMX0R1E	leukaemia	2A60-2B33	Phase 1/2	[10]
CD19 and CD22 CAR-T Cells	DM581CS	B-cell lymphoma	2A86	Phase 1/2	[11]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[13]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[14]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[15]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[16]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[17]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[18]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[19]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[20]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell receptor CD22 (CD22)	TTM6QSK	CD22_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.
• [2] Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
• [3] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
• [4] Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
• [5] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [6] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [7] Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
• [8] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [9] ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
• [10] ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
• [11] ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
• [12] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [13] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [14] Clinical pipeline report, company report or official report of Genmab.
• [15] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [16] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [17] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [18] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [19] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [20] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [21] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.